Small Molecule Antagonists of Cellular Innate Immunity for Enhanced Cell and Gene Therapy Manufacturing

Virica’s latest advancements in using Viral Sensitizers (VSE™) to overcome innate immune barriers in cell and gene therapy manufacturing. Using its High-Throughput Virology (HTV™) platform, Virica identified application-specific VSEs that significantly enhanced AAV production, achieving over 4-fold yield increases in ReiThera’s ReiCell-AAV system and improved lentiviral production and T-cell transduction efficiency. The results demonstrate VSEs’ ability to boost functional titer and reduce required viral vector doses, enabling dose-sparing strategies. Cost modeling further highlights the substantial savings VSE-enabled manufacturing can deliver, making gene therapy production more scalable, accessible, and cost-effective.